lapaquistat

Small moleculeexperimental

Clinical trial activity

16 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
16
Phase 3
13
Phase 4
0

Earliest trial started Sep 1, 2004 (NCT00864643)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2004

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1cccc([C@H]2O[C@H](CC(=O)N3CCC(CC(=O)O)CC3)C(=O)N(CC(C)(C)COC(C)=O)c3ccc(Cl)cc32)c1OC
Mol. weight
645.15 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid
  • (1-(2-(1-(2-carboxyoxy-1,1-dimethylethyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydrobenzo(e)(1,4)oxazepin-3-yl)acetyl)piperidin-4-yl)acetic acid
  • lapaquistat
  • lapaquistat
  • lapaquistat
  • lapaquistat acetate
  • lapaquistat acetate
  • lapaquistat acetate
  • tak475
  • tak 475
  • tak-475
  • tak-475
  • tak-475
  • tak-475

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00532558Phase 3Oct 1, 2007Takeda
NCT00865228Phase 2Jul 1, 2007Takeda
NCT00532311Phase 3Jul 1, 2007Takeda
NCT00286481Phase 3Mar 1, 2006Takeda
NCT00813527Phase 2Feb 1, 2006Takeda
NCT00868127Phase 3Dec 1, 2005Takeda
NCT00249899Phase 3Nov 1, 2005Takeda
NCT00263081Phase 3Nov 1, 2005Takeda
NCT00256178Phase 3Oct 1, 2005Takeda
NCT00251680Phase 3Oct 1, 2005Takeda
NCT00249912Phase 3Oct 1, 2005Takeda
NCT00268697Phase 3Oct 1, 2005Takeda
NCT00143663Phase 3Sep 1, 2005Takeda
NCT00143676Phase 3Aug 1, 2005Takeda
NCT00487994Phase 3Nov 1, 2004Takeda
NCT00864643Phase 2Sep 1, 2004Takeda
Showing 16 of 16 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
TakedaFor profit161622004
1 organizations
Page 1 / 1